Retinoids in Dermatology: Topical and Oral Applications

Retinoids represent one of the most extensively studied and broadly applied drug classes in dermatology, with applications ranging from acne management to chemoprevention of skin cancer. This page covers the classification of retinoids by generation and route of administration, their mechanisms of action, the clinical conditions for which they are prescribed, and the regulatory and safety frameworks that govern their use in the United States. Understanding how retinoids differ from one another — and where each type is appropriate — is foundational to dermatology treatment literacy.

Definition and Scope

Retinoids are synthetic and naturally occurring compounds derived from vitamin A (retinol) that exert their effects by binding to nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs), which regulate gene transcription across a wide range of cellular processes. The U.S. Food and Drug Administration (FDA) has approved multiple retinoid compounds across both topical and systemic formulations, spanning four recognized generations of molecular development.

The four generations are classified based on structural modification:

First generation — naturally occurring compounds, including retinol, retinaldehyde, tretinoin (all-trans-retinoic acid), isotretinoin (13-cis-retinoic acid), and alitretinoin.
Second generation (arotinoids) — etretinate and its active metabolite acitretin, developed to improve pharmacokinetics.
Third generation (polyaromatic retinoids) — adapalene, tazarotene, and bexarotene, engineered for receptor selectivity.
Fourth generation — trifarotene, the first retinoid selective for RAR-γ, FDA-approved in 2019 specifically for truncal acne.

Topical retinoids are classified as prescription drugs by the FDA, with the exception of retinol-containing cosmetic products, which are regulated under the Federal Food, Drug, and Cosmetic Act (FD&C Act) as cosmetics when no drug claims are made. The distinction between cosmetic and drug classification has direct implications for labeling, manufacturing standards, and clinical evidence requirements, a framework detailed under the regulatory context for dermatology.

How It Works

Retinoids modulate gene expression by binding to nuclear receptor heterodimers that attach to retinoic acid response elements (RAREs) in DNA. This mechanism produces effects across four primary biological pathways relevant to dermatology:

Keratinocyte differentiation and proliferation — retinoids normalize the differentiation cycle of epidermal keratinocytes, reducing follicular hyperkeratinization, the root cellular event in acne comedone formation.
Sebaceous gland suppression — oral isotretinoin reduces sebaceous gland size by up to 90%, as documented in studies reviewed by the FDA during its original NDA review process, and decreases sebum production, reducing Cutibacterium acnes colonization.
Collagen synthesis and extracellular matrix remodeling — tretinoin stimulates procollagen type I synthesis and inhibits matrix metalloproteinases (MMPs), mechanisms underlying its use in photoaging management.
Anti-proliferative and pro-apoptotic activity — bexarotene and alitretinoin act through retinoid X receptors to induce apoptosis in malignant T-cells, which forms the basis for their oncologic indications.

Topical retinoids are subject to photodegradation; tretinoin loses stability on UV exposure, which is why evening application is standard clinical practice and why trifarotene and adapalene were engineered for greater photostability.

Common Scenarios

Retinoids are used across a wide spectrum of dermatological conditions. The following structured breakdown maps major clinical applications to the relevant compound and route:

Acne vulgaris
Tretinoin 0.025%–0.1% (topical), adapalene 0.1%–0.3% (topical, with adapalene 0.1% available OTC since 2016 under FDA approval), and trifarotene 0.005% cream (topical) are all FDA-approved first-line or adjunct options. Oral isotretinoin is reserved for severe nodular acne or acne resistant to at least two antibiotic courses, as reflected in the FDA-mandated iPLEDGE program guidelines.

Psoriasis
Acitretin (oral) is FDA-approved for severe plaque psoriasis, often used in combination with phototherapy. Tazarotene 0.05%–0.1% (topical) carries an FDA indication for plaque psoriasis. For more detailed treatment context, see psoriasis types and management.

Photoaging and photodamage
Tretinoin 0.02%–0.1% cream carries an FDA-approved indication for the mitigation of fine facial wrinkles, mottled hyperpigmentation, and tactile roughness — making it one of the few cosmetically relevant drugs with a drug (not cosmetic) designation.

Cutaneous T-cell lymphoma (CTCL)
Bexarotene gel 1% is FDA-approved for early-stage CTCL lesions. Alitretinoin 0.1% gel is approved in the U.S. for AIDS-related Kaposi's sarcoma cutaneous lesions.

Ichthyosis and keratinization disorders
Acitretin is used off-label and in some cases on-label for lamellar ichthyosis, Darier's disease, and palmoplantar keratodermas.

Decision Boundaries

Retinoid selection is governed by indication, route tolerability, teratogenic risk category, and monitoring requirements.

Topical vs. oral: Topical retinoids deliver localized effect with minimal systemic absorption, making them the standard starting point for acne and photoaging. Oral retinoids produce systemic exposure and are reserved for conditions where topical therapy is inadequate or where widespread body surface involvement precludes topical application.

Teratogenicity — the critical safety boundary: All retinoids carry teratogenic risk. Isotretinoin is classified under FDA Pregnancy Category X and is subject to the iPLEDGE REMS (Risk Evaluation and Mitigation Strategy) program, which mandates two forms of contraception for patients of childbearing potential, monthly pregnancy testing, and prescriber, pharmacy, and patient enrollment before dispensing. Acitretin carries a similar REMS-adjacent warning, with the FDA noting that acitretin can convert to etretinate in the presence of alcohol, extending the teratogenic risk window to 3 years post-treatment. Topical tretinoin and adapalene also carry pregnancy-related warnings, though systemic absorption is negligible at standard doses.

Mucocutaneous and systemic side effects: Oral retinoids commonly produce dose-dependent mucocutaneous effects — cheilitis affects more than 90% of isotretinoin users at therapeutic doses. Acitretin is associated with hyperlipidemia and hepatotoxicity, requiring lipid panel and liver function monitoring at baseline and during therapy, per FDA prescribing information.

Receptor selectivity as a differentiator: Third-generation retinoids such as adapalene (RAR-β/γ selective) and trifarotene (RAR-γ selective) produce fewer irritant effects than first-generation tretinoin due to reduced off-target RAR-α binding, making them preferable in patients with sensitive skin or a history of retinoid dermatitis.

The interplay between topical retinoids and other topical medications in dermatology — particularly topical antibiotics and benzoyl peroxide — requires attention to avoid antagonism or excessive skin barrier disruption.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)